Patent: 10,357,476
✉ Email this page to a colleague
Summary for Patent: 10,357,476
| Title: | Method for treating coronary artery disease |
| Abstract: | The use of a combination of carvedilol, metformin, evolocumab, and one or more statins to remove atheromas from coronary arteries and thereby treat coronary artery disease is disclosed. The method treats coronary artery disease by removing one or more atheromas from one or more coronary arteries of a patient by administering a therapeutically effective amount of: (a) carvedilol; (b) metformin; (c) evolocumab; and (d) one or more statins; or a pharmaceutically acceptable salt, prodrug, or derivative of one or more of (a)-(d). In some embodiments, the one or more statins comprise simvastatin. In some embodiments, the one or more statins comprise rosuvastatin. In some embodiments, the one or more statins comprise atorvastatin. In some embodiments, the one or more statins comprise pravastatin. |
| Inventor(s): | Ahmad; Anis (Rock Island, IL) |
| Assignee: | |
| Application Number: | 16/186,495 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,357,476
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 08/27/2015 | ⤷ Try a Trial | 2038-10-30 |
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 07/08/2016 | ⤷ Try a Trial | 2038-10-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
